Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel.
Author: Mizrahi EH, Bowirrat A, Jacobsen DW, Korczyn AD, Traore F, Petot GJ, Lerner AJ, Debanne SM, Adunsky A, Dibello PM, Friedland RP.
Source:
Journal of the neurological sciences, 227(1), 109-113.
High plasma homocysteine (tHcy) is a risk factor for cardiovascular disease and
stroke and Alzheimer's disease (AD). An inverse relationship has been reported
between tHcy and plasma B12 and folate levels. Seventy-nine AD patients and 156
controls from three Arab villages in northern Israel participated. Plasma tHcy,
B12 and folate levels were determined. Data were analyzed using univariate
statistical tests and logistical regression with confounders. tHcy was
significantly higher in AD patients (20.6+/-8.7 micromol/l) than in controls
(16.4+/-6.5 micromol/l) (p=0.03) after correction for year of birth, gender and
smoking status. Plasma B12 (322.9+/-136.0/350.5+/-175.3 pmol/l) and plasma folate
(4.5+/-3.8/4.9+/-2.6 nmol/l) levels did not differ significantly between AD
patients and controls. Subjects in the highest tHcy tertile or in the lowest B12
and folate tertiles did not have greater risk to develop AD. In this population
residing in Arab villages in northern Israel, tHcy levels were significantly
higher among AD patients than in controls. Plasma B12 and folate levels were
lower among cases but were not significant. There was not a significant
association between plasma tHcy, B12 and folate levels in controls or AD
patients. High levels of tHcy may suggest the need for folate and vitamin B12
supplementation in this population.
Publication Types:
Comparative Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.